69 related articles for article (PubMed ID: 23059408)
1. Serum nitric oxide levels in patients with benign and malignant biliary disease: a prospective single center study.
Beyazit Y; Sayilir A; Koklu S; Torun S; Suvak B; Tas A; Purnak T; Kalkan IH; Yesil Y; Ibis M
J Clin Gastroenterol; 2013 Mar; 47(3):258-63. PubMed ID: 23059408
[TBL] [Abstract][Full Text] [Related]
2. Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis.
Beyazit Y; Kekilli M; Ibis M; Kurt M; Sayilir A; Onal IK; Purnak T; Oztas E; Tas A; Yesil Y; Arhan M
Hepatogastroenterology; 2012; 59(117):1469-73. PubMed ID: 22683963
[TBL] [Abstract][Full Text] [Related]
3. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
4. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
5. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
6. Malignant biliary obstruction significantly increases serum lipid levels: a novel biochemical tumor marker?
Yazgan Y; Oncu K; Kaplan M; Tanoglu A; Kucuk I; Dιnc M; Demιrturk L
Hepatogastroenterology; 2012 Oct; 59(119):2079-82. PubMed ID: 23435128
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease.
Natsios A; Vezakis A; Kaparos G; Fragulidis G; Karakostas N; Kouskouni E; Logothetis E; Polydorou A
J BUON; 2015; 20(4):1030-6. PubMed ID: 26416052
[TBL] [Abstract][Full Text] [Related]
8. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
10. Nutritional assessment of patients with benign and malignant obstructions of the biliary tract.
Padillo F; Rodríguez Mf; Hervas A; Miño G; Sitges-Serra A; Pera-Madrazo C
Rev Esp Enferm Dig; 1999 Sep; 91(9):622-9. PubMed ID: 10502710
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study.
Fogel EL; deBellis M; McHenry L; Watkins JL; Chappo J; Cramer H; Schmidt S; Lazzell-Pannell L; Sherman S; Lehman GA
Gastrointest Endosc; 2006 Jan; 63(1):71-7. PubMed ID: 16377319
[TBL] [Abstract][Full Text] [Related]
12. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
Yamaguchi K; Nakamura M; Shirahane K; Konomi H; Torata N; Hamasaki N; Kawakita M; Tanaka M
Dig Liver Dis; 2005 Mar; 37(3):190-4. PubMed ID: 15888284
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases.
Ozkan H; Demirbaş S; Ibiş M; Akbal E; Köklü S
Pancreatology; 2011; 11(3):295-300. PubMed ID: 21757969
[TBL] [Abstract][Full Text] [Related]
14. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic biliary drainage for severe acute cholangitis in biliary obstruction as a result of malignant and benign diseases.
Kumar R; Sharma BC; Singh J; Sarin SK
J Gastroenterol Hepatol; 2004 Sep; 19(9):994-7. PubMed ID: 15304115
[TBL] [Abstract][Full Text] [Related]
16. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
17. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study.
Ramchandani M; Reddy DN; Gupta R; Lakhtakia S; Tandan M; Darisetty S; Sekaran A; Rao GV
Gastrointest Endosc; 2011 Sep; 74(3):511-9. PubMed ID: 21737076
[TBL] [Abstract][Full Text] [Related]
18. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
Koopmann J; Thuluvath PJ; Zahurak ML; Kristiansen TZ; Pandey A; Schulick R; Argani P; Hidalgo M; Iacobelli S; Goggins M; Maitra A
Cancer; 2004 Oct; 101(7):1609-15. PubMed ID: 15378479
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
20. Bile cytology. Diagnostic role in the management of biliary obstruction.
Nilsson B; Wee A; Yap I
Acta Cytol; 1995; 39(4):746-52. PubMed ID: 7631549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
